Show simple item record

dc.contributor.authorCoyle, L
dc.contributor.authorMorley, NJ
dc.contributor.authorRambaldi, A
dc.contributor.authorMason, KD
dc.contributor.authorVerhoef, G
dc.contributor.authorFurness, CL
dc.contributor.authorZhang, A
dc.contributor.authorJung, AS
dc.contributor.authorCohan, D
dc.contributor.authorFranklin, JL
dc.date.accessioned2020-12-14T06:26:59Z
dc.date.available2020-12-14T06:26:59Z
dc.date.issued2020-05-31
dc.identifier.citationCoyle, L., Morley, N. J., Rambaldi, A., Mason, K. D., Verhoef, G., Furness, C. L., Zhang, A., Jung, A. S., Cohan, D. & Franklin, J. L. (2020). Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. LEUKEMIA & LYMPHOMA, 61 (9), pp.2103-2112. https://doi.org/10.1080/10428194.2020.1759055.
dc.identifier.issn1042-8194
dc.identifier.urihttp://hdl.handle.net/11343/254224
dc.description.abstractThe phase 2 portion of this open-label phase 2/3 study assessed the efficacy and safety of blinatumomab as second salvage for aggressive relapsed or refractory (r/r) aggressive B-cell non-Hodgkin lymphoma (B-NHL) following platinum-based first salvage chemotherapy. Forty-one patients with aggressive disease (32% relapsed; 68% refractory) enrolled and received stepwise blinatumomab (9-28-112 μg/day) in a 70-day cycle 1 and an optional 28-day cycle 2; 19 (46%) completed cycle 1 and 3 (7%) completed cycle 2. The overall response rate after 12 weeks was 37%, including 9 (22%) complete metabolic responses. Eight (20%) patients (all responders) subsequently received stem cell transplants. Grade ≥3 adverse events were reported in 29 (71%) patients. Grade 3 cytokine release syndrome occurred in one patient. Grade 3 neurologic events occurred in 10 (24%) patients; all resolved. Blinatumomab monotherapy appears effective as second salvage therapy in patients with r/r aggressive B-NHL. Trial registration: NCT02910063.
dc.languageEnglish
dc.publisherTAYLOR & FRANCIS LTD
dc.titleOpen-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
dc.typeJournal Article
dc.identifier.doi10.1080/10428194.2020.1759055
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.source.titleLeukemia and Lymphoma
melbourne.source.volume61
melbourne.source.issue9
melbourne.source.pages2103-2112
melbourne.elementsid1456585
melbourne.openaccess.urlhttp://doi.org/10.1080/10428194.2020.1759055
melbourne.openaccess.statusPublished version
melbourne.contributor.authorMason, Kylie
dc.identifier.eissn1029-2403
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record